This disclosure provides a method of treating gastrointestinal inflammation such as inflammatory bowel disease (IBS) with a bacteriophage containing composition. The bacteriophage containing composition can be used as prebiotic supplementation and support of the gastrointestinal microflora. This disclosure relates to compositions that comprise one or more types of bacteriophage and methods of using such bacteriophages as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacterial populations and releasing nutrients into the environment for good bacteria in the digestive system of an individual.
